229971-81-7
Chemical Structure
ADH-1
Synonym(s): Exherin
- CAS No.: 229971-81-7
- Formula:C22H34N8O6S2
- Molecular Weight:570.69
IUPAC Name: (4R,7S,10S,13S,16R)-13-((1H-imidazol-5-yl)methyl)-16-acetamido-7-isopropyl-10-methyl-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetraazacycloheptadecane-4-carboxamide
InChIKey: FQVLRGLGWNWPSS-BXBUPLCLSA-N
SMILES: O=C([C@@H](NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CC1=CN=CN1)N2)=O)=O)=O)CSSC[C@H](NC(C)=O)C2=O)N
Biological Activity: ADH-1 (Exherin) is a cyclic pentapeptide N-cadherin antagonist. ADH-1 binds to N-cadherin EC1-2 as an HAV mimetic, competitively blocks homophilic trans interactions, forms a stable protein-drug complex, and induces conformational rearrangement. ADH-1 targets tumor microvasculature, causing vascular injury and apoptosis. ADH-1 inhibits tumor growth and metastasis in mouse tumor models. ADH-1 can be used in cancer-related research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ADH-1 | 99.74% | ADH-1 (Exherin) is a cyclic pentapeptide N-cadherin antagonist. ADH-1 binds to N-cadherin EC1-2 as an HAV mimetic, competitively blocks homophilic trans interactions, forms a stable protein-drug complex, and induces conformational rearrangement. ADH-1 targets tumor microvasculature, causing vascular injury and apoptosis. ADH-1 inhibits tumor growth and metastasis in mouse tumor models. ADH-1 can be used in cancer-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.91
HY-13541AADH-1 TFA -
Similarity Score 0.56
HY-P5322Thrombospondin (TSP-1)-derived CD36 binding motif -
Similarity Score 0.55
HY-P2005Malformin C -
Similarity Score 0.54
HY-P0123SPACE peptide -
Similarity Score 0.54
HY-P2569Malformin A1 -
Similarity Score 0.54
HY-P11709CLPVASC -
Similarity Score 0.54
HY-P11408[D-Cys6,Asn7,D-Ala11,Cys14]-Bombesin (6-14) -
Similarity Score 0.52
HY-19154Montirelin -
Similarity Score 0.51
HY-P1565Transdermal Peptide Disulfide -
Explore the MedChemAI to find more analogs
References
- [1]. Jonker D J, et al. A phase I study of the novel molecularly targeted vascular targeting agent, Exherin (ADH-1), shows activity in some patients with refractory solid tumors stratified according to N-cadherin expression. J Clin Oncol, 2005, 23(16_suppl):3038.
- [2]. Perotti A, et al. Clinical and pharmacological phase I evaluation of ExherinTM (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Annals of Oncology, 2009, 20(4):741-745.
- [3]. Biswas J, et al. Modulation of N-cadherin-mediated homophilic trans interaction upon direct binding of ADH-1: Exploring the molecular basis of action of ADH-1 as N-cadherin inhibitor. Biochimie. 2026 Oct;249:141-149. [Content Brief]